Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials.
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB.
Bhatt SP, et al. Among authors: lu x.
Lancet Respir Med. 2025 Jan 31:S2213-2600(24)00409-0. doi: 10.1016/S2213-2600(24)00409-0. Online ahead of print.
Lancet Respir Med. 2025.
PMID: 39900091